Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, and metabolic diseases. Its research focuses on ion channels, which make up of protein that enables and controls the passage of charged ions across cell membranes. Its product pipeline includes Tesofensine, Tesomet, SAN711, and SAN903. The company was founded by Claus Tycho Bræstrup, Anker Gunvald Lundemose, Jørgen Drejer, Palle Christophersen, and Thomas Feldthus in 2011 and is headquartered Glostrup, Denmark.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company